Skip to main content
European Commission logo print header

Exploitation of genomic variants affecting coronary artery disease and stroke risk for therapeutic intervention

Obiettivo

Atherosclerosis and its most disabling sequelae, coronary artery disease (CAD) and stroke, are leading causes of death in Europe. Until now, preventive and therapeutic interventions for these diseases aim at ameliorating the effects of established cardiovascular risk factors. More recently, results of genome-wide association (GWA) studies added to our perception of mechanisms leading to atherosclerosis. At present, over 40 CAD and several genomic risk loci have been identified, the majority through efforts led by the applicants. Some genes at these loci work through known risk factors such as lipids and, in fact, are already established or evolving treatment targets. However, this is not true for the majority of risk variants, which implies that key pathways leading to atherosclerosis are yet to be exploited for therapeutic intervention. This EU network (CVgenes@target), which brings together an equal number of SME- and academic partners, will utilize genomic variants affecting atherosclerosis risk for identification of both underlying genes and affected pathways in order to identify, characterize, and validate novel therapeutically relevant targets for prevention and treatment of CAD and stroke. In programme 1 we will investigate molecular mechanisms at the genomic loci in order to further unravel causal genes, in programme 2 we will explore in vitro and in vivo whether the pathways disturbed by causal genes are suitable for therapeutic intervention, and in programme 3 we will establish assays and initiate high throughput screens to tackle therapeutically attractive targets. Our resources including large OMICs and state-of-the-art bioinformatics platforms as well as multiple, already established in vitro and in vivo models support the feasibility of the approach. In fact, two genomic risk loci (ADAMTS7 (CAD); HDAC9 (stroke and CAD)), both identified in GWA studies under direction of the applicants, already revealed attractive targets for therapeutic intervention.

Invito a presentare proposte

FP7-HEALTH-2013-INNOVATION-1
Vedi altri progetti per questo bando

Coordinatore

DEUTSCHES HERZZENTRUM MUNCHEN
Contributo UE
€ 853 354,30
Indirizzo
Lazarettstrasse 36
80636 Munich
Germania

Mostra sulla mappa

Regione
Bayern Oberbayern München, Kreisfreie Stadt
Tipo di attività
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Contatto amministrativo
Per Larsen (Mr.)
Collegamenti
Costo totale
Nessun dato

Partecipanti (12)